MX2014011843A - Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. - Google Patents
Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.Info
- Publication number
- MX2014011843A MX2014011843A MX2014011843A MX2014011843A MX2014011843A MX 2014011843 A MX2014011843 A MX 2014011843A MX 2014011843 A MX2014011843 A MX 2014011843A MX 2014011843 A MX2014011843 A MX 2014011843A MX 2014011843 A MX2014011843 A MX 2014011843A
- Authority
- MX
- Mexico
- Prior art keywords
- ewing
- rhabdomyosarcoma
- neuroblastoma
- sarcoma
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un método de tratamiento de un cáncer seleccionado entre el grupo que consiste en neuroblastoma, sarcoma de Ewing, o rabdomiosarcoma, el cual comprende administrar una cantidad terapéuticamente eficaz de un compuesto de la fórmula (I), tal cual se define en el presente documento, o una sal farmacéuticamente aceptable del mismo a un sujeto, preferiblemente un ser humano, en necesidad del mismo; al uso del compuesto de la fórmula (I), o de una sal farmacéuticamente aceptable del mismo, para la elaboración de composiciones farmacéuticas para su uso en el tratamiento de un cáncer seleccionado entre el grupo que consiste en neuroblastoma, sarcoma de Ewing, o rabdomiosarcoma; y al uso del compuesto de la fórmula (1), o de una sal farmacéuticamente aceptable del mismo, en el tratamiento de un cáncer seleccionado entre el grupo que consiste en neuroblastoma, sarcoma de Ewing, o rabdomiosarcoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618215P | 2012-03-30 | 2012-03-30 | |
| PCT/US2013/034214 WO2013148912A1 (en) | 2012-03-30 | 2013-03-28 | Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014011843A true MX2014011843A (es) | 2014-12-10 |
Family
ID=48142079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011843A MX2014011843A (es) | 2012-03-30 | 2013-03-28 | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150051252A1 (es) |
| EP (1) | EP2830619A1 (es) |
| JP (1) | JP2015512416A (es) |
| KR (1) | KR20150002623A (es) |
| CN (1) | CN104244949A (es) |
| AU (1) | AU2013239624A1 (es) |
| CA (1) | CA2865993A1 (es) |
| IN (1) | IN2014DN09013A (es) |
| MX (1) | MX2014011843A (es) |
| RU (1) | RU2014143232A (es) |
| WO (1) | WO2013148912A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015078931A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating neuroblastomas using thienotriazolodiazepine compounds |
| EP3558266B1 (en) * | 2016-12-21 | 2022-03-30 | The Board of Regents of The University of Texas System | Altertoxin ii as a selective inhibitor of ewing family of tumor cells |
| CA3111057A1 (en) * | 2018-08-28 | 2020-02-05 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| CA2710122A1 (en) * | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| IN2012DN01961A (es) * | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
| CN103619840B (zh) * | 2011-06-21 | 2016-01-20 | 诺华股份有限公司 | (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物 |
| ES2676180T3 (es) * | 2011-07-01 | 2018-07-17 | Novartis Ag | Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer |
| WO2013049581A1 (en) * | 2011-09-30 | 2013-04-04 | Beth Israel Deaconess Medical Center Inc. | Compositions and methods for the treatment of proliferative diseases |
| US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
-
2013
- 2013-03-28 JP JP2015503554A patent/JP2015512416A/ja active Pending
- 2013-03-28 EP EP13717371.2A patent/EP2830619A1/en not_active Withdrawn
- 2013-03-28 MX MX2014011843A patent/MX2014011843A/es unknown
- 2013-03-28 US US14/387,636 patent/US20150051252A1/en not_active Abandoned
- 2013-03-28 CA CA2865993A patent/CA2865993A1/en not_active Abandoned
- 2013-03-28 CN CN201380012051.XA patent/CN104244949A/zh active Pending
- 2013-03-28 RU RU2014143232A patent/RU2014143232A/ru unknown
- 2013-03-28 AU AU2013239624A patent/AU2013239624A1/en not_active Abandoned
- 2013-03-28 KR KR1020147026928A patent/KR20150002623A/ko not_active Application Discontinuation
- 2013-03-28 WO PCT/US2013/034214 patent/WO2013148912A1/en active Application Filing
-
2014
- 2014-10-28 IN IN9013DEN2014 patent/IN2014DN09013A/en unknown
-
2016
- 2016-02-08 US US15/018,287 patent/US20160151344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015512416A (ja) | 2015-04-27 |
| US20150051252A1 (en) | 2015-02-19 |
| CA2865993A1 (en) | 2013-10-03 |
| EP2830619A1 (en) | 2015-02-04 |
| AU2013239624A1 (en) | 2014-10-02 |
| CN104244949A (zh) | 2014-12-24 |
| WO2013148912A1 (en) | 2013-10-03 |
| KR20150002623A (ko) | 2015-01-07 |
| US20160151344A1 (en) | 2016-06-02 |
| IN2014DN09013A (es) | 2015-05-22 |
| RU2014143232A (ru) | 2016-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| NZ726366A (en) | Syk inhibitors | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MD4736C1 (ro) | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| PH12015502365A1 (en) | Bace1 inhibitors | |
| MX2015004362A (es) | Derivados de ketamina. | |
| WO2013085849A3 (en) | Sulfate esters of noribogaine | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
| MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| TW201129361A (en) | Methods for treating pain | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| MX358198B (es) | Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino. | |
| WO2016119031A8 (pt) | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase | |
| IN2013MU01154A (es) | ||
| IN2013MU01155A (es) | ||
| IN2013MU01241A (es) |